Novartis AG NVS
160.32 USD 0.00 (+0.00%)
Nov 12, 2026, 10:19 AM EST
160.05 Day range 161.31
123.24 52-week range 170.46
- YTD
- +16.28%
- 1 year
- +21.19%
News
benzinga.com PepGen Stock Doubles in One Session - Here's Why PepGen reports positive Phase 2 results for PGN-EDODM1 in DM1, showing record splicing correction and notable functional improvements.
defenseworld.net Commonwealth Equity Services LLC Purchases 3,997 Shares of Novartis AG $NVS Commonwealth Equity Services LLC increased its holdings in Novartis AG (NYSE: NVS) by 2.7% in the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 152,688…
zacks.com 3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026 In the Large-Cap Pharmaceuticals industry, LLY, NVS and BAYRY are worth watching as the industry shows a strong recovery.
benzinga.com $1000 Invested In Novartis 5 Years Ago Would Be Worth This Much Today Novartis (NYSE:NVS) has outperformed the market over the past 5 years by 6.13% on an annualized basis producing an average annual return of 15.55%. Currently, Novartis has a market capitalization of…
benzinga.com BioArctic AB Announces Novartis Terminates Their 2025 Option, Collaboration And License Deal; BioArctic To Retain Full $30M Upfront Payment BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered…
benzinga.com Allarity Therapeutics Settles $4.9M Novartis Liability For $1M Payment On October 28, 2026, Allarity Therapeutics, Inc. (the "Company") entered into a Settlement and Release Agreement (the "Settlement Agreement") with Novartis Pharma AG ("Novartis") relating to an
benzinga.com Monte Rosa To Receive $37.5M Milestone Payment From Novartis Following Initiation Of Second Phase 2 Trial Of MRT-6160 In Psoriatic Arthritis Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that its collaborator Novartis has…
benzinga.com Monte Rosa Says Its Collaborator Novartis Initiates Second Phase 2 Clinical Study For VAV1-Directed MGD MRT-6160 In People Living With Active Moderate To Severe Psoriatic Arthritis Phase 2 study to be conducted in participants with active moderate to severe psoriatic arthritisNovartis conducting study under global exclusive development and commercialization license agreement…
benzinga.com Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit Novartis beat Q3 adjusted earnings estimates despite a $1.9 billion Avidity impairment charge, lifted by strong sales of Kisqali, Kesimpta, and revised guidance.
benzinga.com Novartis Q3 2026 Earnings Call Transcript Novartis (NYSE:NVS) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Stock Market Today: Dow Jones, S&P 500, Nasdaq 10 Futures Gain as Fed Begins Its Two-Day Meet— Novartis, HSBC, Welltower in Focus (UPDATED) U.S. stock futures were mixed on Tuesday, as the Dow Jones, S&P 500, and Nasdaq 100 indices moved in different directions.- benzinga.com Novartis Keeps FY 2026 Net Sales Growth At Low Single-Digit, Raises Core Operating Income Outlook To In Line To Low Single-Digit Growth Full-year 2026 guidance raised for core operating income o Net sales expected to grow low single-digit (unchanged) o Core operating income expected to be in line to grow low single-digit (from…
benzinga.com Novartis Q3 Adj. EPS $2.46 Beats $2.27 Estimate, Sales $14.522B Miss $14.582B Estimate Novartis (NYSE:NVS) reported quarterly earnings of $2.46 per share which beat the analyst consensus estimate of $2.27 by 8.37 percent. This is a 9.33 percent increase over earnings of $2.25 per share…
benzinga.com Stock Market: Will S&P 500 Open Up or Down Today? Futures edge higher as earnings, the Fed meeting and Anthropic IPO drive markets; oil falls as traders see 67% odds of an S&P 500 up open.
benzinga.com Visa, Coca-Cola On Deck Tuesday As Payments Growth, Global Demand Face Test Visa is Tuesday’s most material report, with investors looking for continued payments growth after a strong run in the stock. Coca-Cola, HSBC Holdings, Novartis, Boeing and S&P Global report before…
benzinga.com FDA Greenslights Novartis's Rhapsido as First Treatment for Chronic Friction Hives FDA approves Novartis’s Rhapsido for symptomatic dermographism, marking the first treatment for adults with friction-triggered chronic hives- benzinga.com Novartis Receives FDA Approval For Rhapsido To Treat Symptomatic Dermographism https://www.novartis.com/news/media-releases/novartis-rhapsido-remibrutinib-receives-fda-approval-first-treatment-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-cs…
benzinga.com Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease Celldex posts positive Phase 3 data for barzolvolimab to treat chronic spontaneous urticaria. The company plans a 2027 FDA submission.
benzinga.com Novartis Halts Experimental ALS Drug Trial but Acquires Brain Delivery Platform Novartis halted its mid-stage ALS drug trial for VHB937 but exercised a $125 million option to acquire Sironax's brain delivery platform.
benzinga.com Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks Artisan Partners calls on Novartis to revamp board governance and acquisition oversight following sharp stock declines after trial setbacks.- benzinga.com HSBC Upgrades Novartis to Hold, Raises Price Target to $136 HSBC analyst Rajesh Kumar upgrades Novartis (NYSE:NVS) from Reduce to Hold and raises the price target from $123 to $136.
benzinga.com Nvidia, FAA Join Palantir’s AI Expansion as Cyber Push Takes Off Palantir expands its AI footprint via new enterprise deployments, a free cybersecurity initiative, and an upgraded sovereign AI partnership with Fujitsu.
benzinga.com A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower Sarepta Therapeutics shares react to Novartis Phase 3 trial results in DM1 while Sarepta progresses its SRP-1003 RNA therapy clinical trials.
benzinga.com Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.
benzinga.com QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000 Amgen sank 9.8% Tuesday after Novartis' pelacarsen missed its Phase 3 endpoint, casting doubt on rival Lp(a) drug olpasiran.
benzinga.com S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today Crude near $98 pushes the 10-year Treasury yield above 4.8% for the first time since 2023, hammering the Dow as traders price a Fed rate hike next week.
benzinga.com What's Going On With Amgen Stock Tuesday? AMGN stock dips 9% after rival drug trial misses goal. Discover Amgen key support levels, technical outlook, and analyst price targets- benzinga.com Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, and several biotech shares surged or plunged.
benzinga.com Why Is Eli Lilly Stock Falling Tuesday? Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown, and market outlook analyzed.
benzinga.com Stock Market Today: S&P 500, Dow, Nasdaq 100 Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus (UPDATED) Stock Market Today: S&P 500, Dow Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus
benzinga.com Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
benzinga.com Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impacting Ionis and Royalty Pharma shares.- benzinga.com Market-Moving News for September 8th NVS: -13% | Novartis shares are trading lower after the company announced the pelacarsen phase III Lp(a)HORIZON trial did not meet its primary endpoint. IONS: -13% | Ionis Pharmaceuticals shares are…
benzinga.com Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket iSpecimen surged 27.9% premarket on a $4.5M Foldlab AI asset deal; CEA Industries led gainers, while Focus Universal plunged 51.2%.
benzinga.com United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s earnings expected.
benzinga.com Brent Jumps to $97, German AfD Party Wins Big: Stock Market Today Europe closed mixed as the AfD's Saxony-Anhalt landslide and $97 Brent lifted bond yields, and Wall Street sat out Labor Day.- benzinga.com Novartis’ Pelacarsen Phase III Lp(a)HORIZON Trial Fails Primary Cardiovascular Endpoint; Lowered Lp(a) Levels But Did Not Reduce CV Events Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of reducing the risk of cardiovascular events,…
benzinga.com A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effects spark safety concerns.
benzinga.com The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win Novartis stock spikes 5% on positive Phase 3 REMODEL trial results for relapsing MS drug remibrutinib with no liver safety signals.
benzinga.com Yext Posts Upbeat Q2 Earnings, Joins Fervo Energy, MiniMed Group And Other Big Stocks Moving Higher On Tuesday U.S. stocks were lower, with the Nasdaq Composite falling around 1% on Tuesday. Shares of Yext Inc (NYSE:YEXT) rose sharply after the company reported better-than-expected second-quarter earnings.…
benzinga.com Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's strong CML trial data & $8.8B market potential.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in US Trump says imported generic drugs face 0% tariffs for 2 years, before 100% and then 200% duties.
benzinga.com Earnings Scheduled For July 21, 2026 Companies Reporting Before The Bell • Mueller Industries (NYSE:MLI) is projected to report quarterly earnings at $1.15 per share on revenue of $1.27 billion. • Valmont Industries (NYSE:VMI) is…
benzinga.com What's Going on with Vera Therapeutics Stock on Monday? Vera Therapeutics awaits the FDA's July 7 decision on atacicept for IgA nephropathy as investors weigh trial data and competition from Novartis.
benzinga.com Warren Says Trump's Law Pushed 2 Million-Plus Children Off Medicaid, CHIP Across States Elizabeth Warren warns Trump's law pushed children off Medicaid and CHIP in many states, while also challenging TrumpRx's impact on drug costs.
benzinga.com Relay Therapeutics Reports Early Success For Investigational Drug In Rare Vascular Disorders Relay Therapeutics reported early Phase 2 data showing lesion reduction and symptom improvement with zovegalisib.
benzinga.com PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers PTC Therapeutics stock drops after PIVOT-HD update, as FDA approval doubts offset dose-based benefits and stable safety signals.- benzinga.com Earnings Scheduled For April 28, 2026
benzinga.com FDA Adverse Event Monitoring System Q4 2025 Flags Multiple Potential New Drug Safety Signals, Including Hypersensitivity, Hypogammaglobulinemia, Colitis, Aplastic Anemia And Rhabdomyolysis Under Evaluation https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda